News >

Expert Discusses MINDACT, TAILORx Studies in Breast Cancer

Brandon Scalea
Published: Monday, Oct 29, 2018

Dr. Elizabeth A. Mittendorf

Michelle E. Melisko, MD
Although chemotherapy may have a lesser role in breast cancer treatment for select patients, there are still high-risk populations who will derive benefit from this modality, said Michelle E. Melisko, MD.

State of the Science Summit™ on Breast Cancer, Melisko, a clinical professor of medicine at the University of California, San Francisco, discussed the clinical implications of the TAILORx and MINDACT studies.

OncLive: Please provide an overview of your presentation at the State of the Science Summit.TM

Melisko: I reviewed the clinical trials that have recently been published and presented, including MINDACT for MammaPrint and the TAILORx trial, which looked at the value of the Oncotype DX assay to predict the benefit of chemotherapy in patients with HR-positive, HER2-negative breast cancer. I gave a brief historical reference of how we used to give chemotherapy to almost all patients with estrogen receptor (ER)-positive, HER2-negative breast cancers.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Real-World Evidence to Inform Treatment and Management of ER+ Metastatic Breast CancerDec 31, 20191.0
Medical Crossfire®: A Critical Assessment of Current and Emerging Data Sets to Move Treatment of Triple-Negative Breast Cancer ForwardJan 31, 20201.0
Publication Bottom Border
Border Publication